Literature DB >> 8895598

Regulation of hepatic insulin receptors by pancreatic polypeptide in fasting and feeding.

N E Seymour1, A R Volpert, D K Andersen.   

Abstract

Pancreatic polypeptide (PP) increases hepatic insulin receptor (IR) binding activity in fasted PP-deficient rats, but not fasted normal animals. PP-induced alteration of hepatic IR levels in normal animals may be detectable in the fed state when IR concentrations are lower than during fasting. In the current study, the effect of exogenous PP on IR concentrations in the fed and fasted states was determined in healthy 300- to 350-g male Sprague-Dawley rats. Ten animals were administered PP 100 microgram/kg/day for 3 days by intraperitoneal injection and 10 weight-matched control animals received saline vehicle. Five PP- and five saline-administered rats were fasted for 12 hr prior to organ procurement, while 5 PP- and 5 saline-treated rats were given free access to food for this period. Livers were removed and snap-frozen. IRs were isolated from solubilized hepatocyte membranes by affinity chromatography with agarose-bound wheat germ agglutinin. Western blots were performed using a specific antibody to the beta subunit of the IR, which was detected by a chemiluminescence technique after 45-min exposure to X-ray film. Exposed films were examined by scanning densitometry and IR concentration was expressed as absorbance units per milligram of hepatic protein (mean +/- SE). Statistical comparisons were by Student's t test with significance taken at P < 0.05. Feeding was associated with a significantly lower IR concentration in saline-administered animals compared with the fasted state (24.2 +/- 4.0 vs 53.3 +/- 11.1). PP administration in fed rats resulted in significantly increased IR concentration as compared with that seen in saline-administered fed animals (43.8 +/- 8.9 vs 24.2 +/- 4.0). This difference may be due to increased IR synthesis with long-term PP administration, and supports the role of PP as a regulatory factor in hepatic carbohydrate metabolism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895598     DOI: 10.1006/jsre.1996.9999

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  8 in total

1.  Human pancreatic polypeptide in a phospholipid-based micellar formulation.

Authors:  Amrita Banerjee; Hayat Onyuksel
Journal:  Pharm Res       Date:  2012-03-08       Impact factor: 4.200

2.  Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy.

Authors:  Atoosa Rabiee; Panagis Galiatsatos; Rocio Salas-Carrillo; Michael J Thompson; Dana K Andersen; Dariush Elahi
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

Review 3.  Hepatic steatosis in type 1 diabetes.

Authors:  Simon E Regnell; Åke Lernmark
Journal:  Rev Diabet Stud       Date:  2012-02-10

Review 4.  Genetic and dietary salt contributors to insulin resistance in Dahl salt-sensitive (S) rats.

Authors:  Marlene F Shehata
Journal:  Cardiovasc Diabetol       Date:  2008-04-08       Impact factor: 9.951

5.  Discovery of Small-Molecule Modulators of the Human Y4 Receptor.

Authors:  Gregory Sliwoski; Mario Schubert; Jan Stichel; David Weaver; Annette G Beck-Sickinger; Jens Meiler
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

6.  Pancreatic Polypeptide but Not Other Members of the Neuropeptide Y Family Shows a Moderate Association With Perceived Anxiety in Obese Men.

Authors:  Selina Johanna Schaper; Tobias Hofmann; Ellen Wölk; Elena Weibert; Matthias Rose; Andreas Stengel
Journal:  Front Hum Neurosci       Date:  2020-10-19       Impact factor: 3.169

Review 7.  Mechanisms of Post-Pancreatitis Diabetes Mellitus and Cystic Fibrosis-Related Diabetes: A Review of Preclinical Studies.

Authors:  Eleonóra Gál; Jurij Dolenšek; Andraž Stožer; László Czakó; Attila Ébert; Viktória Venglovecz
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-10       Impact factor: 5.555

8.  A novel peptide nanomedicine for treatment of pancreatogenic diabetes.

Authors:  Amrita Banerjee; Hayat Onyuksel
Journal:  Nanomedicine       Date:  2013-01-22       Impact factor: 5.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.